CHRS Stock Forecast: Coherus Oncology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.37
−4.44% on the day

The median 12-month analyst price target for Coherus Oncology, Inc. is $7.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$57.2M
Ticker Nerd rank
38/ 100
Median analyst target
$7.50
Analysts covering
6
Revenue$14.3M+39.5% y/y
Operating income−$32.3M
Net income−$20.6M
Free cash flow−$62.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.7%
1M
−63.0%
YTD
−74.0%
1Y
−66.4%
From 52W high
−85.3%
From 52W low
0.0%
$0.37
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
95
Quality
52
Volatility
49
Accruals
46
Value
40
Revisions
36
Momentum
19
Issuance
12

Growth (95): Sales and profits are climbing, and climbing faster than before.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CHRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26CHRSHigh $10.00Median $7.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5
Buy
1
Hold
0
Sell
$4.00
Low
$7.50
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Nov 2026GuggenheimMaintainsBuy$10 → $8.00
29 Oct 2026HC Wainwright & Co.AssumesBuy$7.00
7 Aug 2026GuggenheimMaintainsBuy$12 → $10
11 May 2026GuggenheimInitiatesBuy—
22 Jan 2026OppenheimerInitiatesOutperform—
4 Sept 2025Maxim GroupUpgradeBuy—
29 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Apr 2025UBSMaintainsNeutral—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024BairdMaintainsOutperform—
4 Dec 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024BairdMaintainsOutperform—
7 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024UBSDowngradeNeutral—
5 Aug 2024HC Wainwright & Co.ReiteratesBuy—
1 July 2024BairdMaintainsOutperform—
24 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CHRS.

Market Radar

This page is one stock. Monday covers all of them.

CHRS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CHRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Coherus Oncology, Inc. returned −66.4% against +6.9% for the S&P 500, dividends included.

CHRS vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26CHRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CHRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 64% of US stocks

Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
70.4%

Higher than 83% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−275.2%

Higher than 5% of US stocks

Return on assets
−26.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Coherus Oncology, Inc. has a market value of $57.2M and an enterprise value of $43.1M.

  • Revenue in the twelve months to 30 June 2026: $50.9M. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: −$132.1M, a −259.4% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.03.

  • Free cash flow in the twelve months to 30 June 2026: −$186.0M.

  • Shares outstanding: 154.5M.

  • Coherus Oncology, Inc. employs 145 people — $351K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CHRS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CHRSCoherus Oncology, Inc.$57.2M38
CGTXCognition Therapeutics, Inc.$55.4M47
AZRAzora Therapeutics, Inc.$55.0M16
OKYOOKYO Pharma Ltd.$55.0M26
AVXLAnavex Life Sciences Corp.$54.8M20
BOLDBoundless Bio, Inc.$54.8M93
NORDNordicus Partners Corp.$54.4M25

Take a look at CHRS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CHRS

What is the CHRS stock price forecast for 2026-2027?

The median 12-month analyst price target for Coherus Oncology, Inc. is $7.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHRS stock a buy right now?

Of the 6 analysts covering Coherus Oncology, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHRS?

As at 21 Nov 2026, Coherus Oncology, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).

Will CHRS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $7.5, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHRS stock forecast for 2030?

No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has CHRS stock performed over the past year?

Coherus Oncology, Inc. returned -66.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Coherus Oncology, Inc. do?

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types.

Company

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.

CEO Mr. Dennis M. Lanfear · 145 employees · United States · https://www.coherus.com